摘要
目的探讨益心康泰联合舒利迭治疗慢性阻塞性肺疾病(COPD)稳定期的临床有效性及安全性。方法选取86例于2015年2月至2016年10月入院治疗的COPD患者,随机分为对照组和研究组,每组43例。对照组给予舒利迭治疗,研究组加用益心康泰胶囊,并根据病情调整剂量。治疗6个月后,比较两组的治疗效果。结果经治疗,研究组患者FEV1、FVC和FEV1/FVC均明显高于对照组,6-MWT明显长于对照组,组间比较差异显著(P<0.05)。两组患者的SGRQ评分均显著降低,且研究组评分明显低于对照组(P<0.05)。两组患者均未见严重不良反应,轻微症状在稍作调养后即消失。研究组和对照组不良反应总发生率分别为9.3%和7.0%,组间比较无明显差异(P>0.05)。结论益心康泰联合舒利迭治疗COPD效果显著,肺功能改善明显,且患者耐受性良好,无严重不良反应,值得临床推广应用。
Objective To investigate the effect of Yixin Kangtai cap sule combined with seretide in the treatment of chronic obstructive pulmonary disease（COPD） clinical efficacy and safety in stable period. Methods A total of 86 cases of COPD patients admitted in our hospital from February 2015 to October 2016 were divided into control group and study group, with 43 cases in each group. The control group was treated with seretide, and the study group added the Yixin Kangtai capsule and adjusted the dose according to the condition of the disease. After 6 months of treatment, the treatment effects between the groups were compared. Results After treatment, the FEV1, FVC and FEV1/FVC in the study group were significantly higher than those in the control group, the 6-MWT was significantly longer than that in the control group, the differences were significant between the two groups（P〈0.05）. The SGRQ scores of the two groups decreased significantly,and the score of the study group was significantly lower than that of the control group（P〈0.05）. There was no serious adverse reactions in the two groups, and the mild symptoms disappeared after a slight adjustment. The total incidence of adverse reactions in the study group and the control group was 9.3% and 7.0% respectively, and there was no significant difference between the two groups（P〉0.05）. Conclusion Kangtai Yixin capsule combine with seretide in the treatment of COPD has significant effect, it can improve pulmonary function, with well tolerated and serious adverse reactions, which is worthy of clinical application.
作者
白亮亮
BAI Liang-liang(Yulin No.2 匀ospital, Yulin 719000, China)
出处
《临床医学研究与实践》
2018年第12期120-121,共2页
Clinical Research and Practice
